SIREN L L C
Q3 2025 Form 13-F
GREENWICH, DELAWARE
CIK 0002005245
· Institutional investment manager
Consolidated report · includes
2 managers
since Q3 2024
$2.6B Reported Value Total
Reported value
$2.6B
Quarter over quarter
+31.3%
Holdings
115
Top-10 concentration
47.5%
Filing Structure
Reports holdings for
- Invus Financial Advisors LLC · File #028-19938 · since Q3 2024
- Invus Group, LLC (not a 13F filer in our records) · File #028-24462 · since Q3 2024
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Raymond Debbane
President
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2025 13F record
Q3 2025 13F filing summary
| Period of report | September 30, 2025 |
|---|---|
| Filed | November 13, 2025 |
| Form | 13F-HR |
| Reported value | $2.6B |
| Positions | 115 |
| Change in reported value | +32.3% |
| New positions | 24 |
| Exited positions | 19 |
| Position turnover | 32.1% |
| Top-10 concentration | 47.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 12, 2026
|
110 | $4.2B |
|
Q2 2026 13F
Filed Aug 13, 2026
|
115 | $4.9B |
|
Q1 2026 13F
Filed May 14, 2026
|
100 | $3.6B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
113 | $3.4B |
|
Q3 2025 13F
Filed Nov 13, 2025
|
115 | $2.6B |
|
Q2 2025 13F
Filed Aug 13, 2025
|
110 | $1.9B |
|
Q1 2025 13F
Filed May 14, 2025
|
116 | $1.8B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
117 | $2.3B |
|
Q3 2024 13F
Filed Nov 13, 2024
|
109 | $2.0B |
Top 20 holdings · Q3 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SRRK Scholar Rock Holding Corp | $344.5M | 13.48% |
| 2 | KYMR Kymera Therapeutics Inc | $194.0M | 7.59% |
| 3 | ONC BeOne Medicines AG | $168.0M | 6.57% |
| 4 | ARWR Arrowhead Pharmaceuticals Inc | $92.1M | 3.6% |
| 5 | BCAX Bicara Therapeutics Inc | $82.4M | 3.22% |
| 6 | CNTA Centessa Pharmaceuticals PLC | $78.3M | 3.06% |
| 7 | CRNX Crinetics Pharmaceuticals Inc | $70.3M | 2.75% |
| 8 | EWTX Edgewise Therapeutics Inc | $63.2M | 2.47% |
| 9 | IRON Disc Medicine Inc | $60.4M | 2.36% |
| 10 | DYN Dyne Therapeutics Inc | $59.8M | 2.34% |
| 11 | APLS Apellis Pharmaceuticals Inc | $58.3M | 2.28% |
| 12 | RNA Avidity Biosciences Inc | $56.0M | 2.19% |
| 13 | STOK Stoke Therapeutics Inc | $52.8M | 2.07% |
| 14 | LXRX Lexicon Pharmaceuticals Inc | $52.5M | 2.06% |
| 15 | RYTM Rhythm Pharmaceuticals Inc | $50.5M | 1.98% |
| 16 | TNGX Tango Therapeutics Inc | $49.4M | 1.93% |
| 17 | RVMD Revolution Medicines Inc | $48.7M | 1.91% |
| 18 | ASND Ascendis Pharma A/S | $46.9M | 1.83% |
| 19 | RZLT Rezolute Inc | $45.8M | 1.79% |
| 20 | SLDB Solid Biosciences Inc | $45.8M | 1.79% |
Values as reported on the Q3 2025 Form 13F. Every position is in the holdings table below.